Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system.

Abstract

BACKGROUND:

Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl™) was previously shown to competitively inhibit mushroom and human tyrosinase in vitro without the associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma.

OBJECTIVE:

The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oligopeptide cream, an antioxidant cleanser, 20% glycolic acid lotion and physical sunscreen) accelerates clearance of mild-to-moderate melasma.

RESULTS:

All patients showed improvement in their facial melasma with 1 of 4 patients showing complete clearance after just 6 weeks.

CONCLUSIONS:

Results suggest that this regimen may be a useful new tool to treat mild to moderate melasma.

• Authors: Basil M Hantash, Felipe Jimenez
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 11 Issue 5 Pg. 660-2 (May 2012) ISSN: 1545-9616 [Print] United States
• PMID: 22527440 (Publication Type: Case Reports, Journal Article)

Chemical References

• Dermatologic Agents
• Lumixyl
• Oligopeptides

Topics

• Administration, Cutaneous
• Adult
• Dermatologic Agents (administration & dosage, therapeutic use)
• Face
• Female
• Humans
• Male
• Melanosis (drug therapy, pathology)
• Middle Aged
• Oligopeptides (administration & dosage, therapeutic use)
• Severity of Illness Index
• Treatment Outcome